A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

NCT01209130 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

Interventions

DRUG: DCDT2980S
DRUG: rituximab

Sponsor

Genentech, Inc.